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Twelve subjects participated in an open-label, single-dose, balanced three-way crossover study in which the
absorptions of lomefloxacin were compared following (i) an overnight fast, (ii) a carbohydrate meal, and (iii)
a high-fat meal. The time to peak concentration of lomefloxacin was delayed, but peak concentration in plasma
and amount of drug absorbed were unchanged following both meals.
Lomefloxacin [1-ethyl-6, 8-difluoro- 1,4-dihydro-7-(3-
methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid] is a
fluoroquinolone antibacterial agent which is currently under-
going clinical development. Like other members of this
class, lomefloxacin has a broad spectrum of bactericidal
activity against gram-negative and gram-positive bacteria.
This drug shares with other newer fluoroquinolones the
additional advantage of a relatively long elimination half-life
(7 to 8 h) (J. Woodworth and S. Fitzsimmons, Program
Abstr. 29th Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. no. 1268, 1989).
The influence of food on drug absorption is complex and
often unpredictable. Different food components can have
different effects, and food may have opposite effects on
absorption of different drugs, even those which are chemi-
cally related (4). Therefore, the previous demonstration that
food has only slight effects on the absorption rates of
enoxacin (5) and ciprofloxacin (2) gives no guarantee of a
similar outcome with lomefloxacin.
(This study was previously reported in part [W. D.
Hooper, R. G. Dickinson, and M. J. Eadie, 29th ICAAC,
abstr. no. 1274, 1989].)
Twelve fully informed volunteers (eight males and four
females) participated in the study, which had the prior
approval of the Human Experimentation Ethical Review
Committee of The University of Queensland. The study
protocol permitted enrollment of males and females ran-
domly, and no allowance was made in the timing of the
studies for the hormonal cycle of females. The volunteers'
ages were 19 to 22 years (mean, 20 years), weights ranged
from 54 to 79 kg (mean, 67 kg), and all were nonsmokers.
The health of the subjects was assessed by physical exami-
nation and biochemical, hematological, and urine screening.
Each subject took a single 400-mg dose of lomefloxacin
(two capsules containing 200 mg of lomefloxacin as the
hydrochloride, taken with 200 ml of water) on three occa-
sions with a 7-day interval between doses. The study fol-
lowed an open-label, balanced three-way crossover design,
with each subject receiving lomefloxacin (i) after a 12-h
overnight fast, (ii) within 5 min after eating a standard
carbohydrate breakfast, and (iii) within 5 min after eating a
high-fat breakfast. The carbohydrate breakfast (fruit juice,
cereal, toast, and coffee) contained 605 calories (70% carbo-
hydrates, 22% fat, and 8% protein), and the high-fat break-
fast (fruit juice, fried eggs and bacon, toast, and coffee)
contained 612 calories (25% carbohydrates, 62% fat, and
* Corresponding author.
13% protein). After the fasting dose, no food was allowed for
4 h. All subjects abstained from alcohol intake from 3 days
prior to the first dose of lomefloxacin until after the comple-
tion of the study. Venous blood samples were collected just
prior to the lomefloxacin dose and at the following times
postdose: 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.25, 2.5,
3.0, 3.5, 4, 6, 8, 10, 12, 24, 32, and 48 h. Samples to 12 h were
collected via an indwelling forearm venous catheter, and
samples thereafter were collected by separate venipuncture.
Blood (10 ml) was collected into tubes containing lithium
heparin (125 IU); the specimens were centrifuged, and the
plasma was separated and frozen (-20°C) within 30 min. All
urine was collected for 72 h postdose over the following
intervals: 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, and 48 to
72 h. Urine pH and volume were recorded at the end of each
collection interval, and a 20-ml sample was stored at -20°C
until analyzed. Appropriate precautions were taken to pro-
tect samples from exposure to light during collection, stor-
age, and analysis.
Lomefloxacin in plasma was assayed by high-performance
liquid chromatography using fluorescence detection. The
method used was adopted without significant modification
from an analytical report supplied by G. D. Searle. The
internal standard was a structural analog, KK-123. In brief,
plasma specimens (0.5 ml) were extracted at pH 7 with
chloroform-isoamyl alcohol (95:5; 5.0 ml), the aqueous
phase and precipitated proteins were removed by aspiration,
and the organic phase was evaporated at 40°C under a
nitrogen stream. The residue was reconstituted in high-
performance liquid chromatography mobile phase (0.5 ml),
and a sample (30 ,ul) was applied to the high-performance
liquid chromatograph. The mobile phase was 22% acetoni-
trile and 1% ammonium acetate (1.0 M) in citric acid (0.05
M), at a flow rate of 1.3 ml/min. We used a Waters
,uBondapak C18 (10 ,um) steel-jacketed column (30 cm by 3.9
mm [inner diameter]). Under these conditions, the retention
time of lomefloxacin was approximately 6.5 min and that of
KK-123 was approximately 12.5 min. The detector was a
Hitachi F-1000 fluorescence spectrophotometer with an ex-
citation wavelength of 280 nm and emission monitored at 455
nm. The signal was recorded with a Shimadzu CR3-A
integrator with FDD-1A floppy disk drive and cathode-ray
tube display. Peak areas were measured.
The precision and accuracy of the method in the assay of
study plasma samples were determined by analysis of seeded
controls processed with each sample batch. This showed
precisions (relative standard deviations) of 7.3% at 0.2
,ug/ml, 8.3% at 1.0 ,ug/ml, and 5.9% at 5.0 ,ug/ml. Accuracies
were 5.4% at 0.2 ,ug/ml, 6.5% at 1.0 ,ug/ml, and 5.7% at 5.0
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FIG. 1. Mean plasma lomefloxacin concentration-time profiles in 12 subjects after a 400-mg oral dose fasting and after a carbohydrate or
high-fat meal. (Data are shown only to 12 h for clarity, but concentrations were measurable at 48 h in every instance.)
,ug/ml. The minimum quantifiable concentration was 20
ng/ml in plasma.
Lomefloxacin in urine was assayed by high-performance
liquid chromatography using an identical procedure. Assays
were done directly on urine to determine the concentration
of lomefloxacin eliminated unchanged (i.e., free lomefloxa-
cin) and on urine following base hydrolysis to determine the
concentration of free lomefloxacin plus lomefloxacin liber-
ated from conjugates. The extent of lomefloxacin conjuga-
tion was obtained by the difference. Data supplied by G. D.
Searle indicated that the conjugate was predominantly the
acyl glucuronide.
Linearity was demonstrated on three occasions over the
concentration range of 3 to 1,000 ,ug/ml, and the minimum
quantifiable concentration was determined as 3 ,ug/ml. The
precision and accuracy of the method in the assay of study
urine samples were determined by analysis of seeded con-
trols processed with each sample batch. This showed preci-
sions (relative standard deviations) of 8.0% at 3 ,ug/ml, 9.3%
at 30 ,ug/ml, and 5.3% at 300 ,ug/ml. Accuracies were 13.5%
at 3 ,ug/ml, 8.2% at 30 ,ug/ml, and 5.0% at 300 ,ug/ml. In the
calculation of lomefloxacin conjugates, difference values of
<2 ,ug/ml were disregarded.
Pharmacokinetic parameters were calculated by model-
independent methods as follows. Maximum concentration
in plasma and the time to reach the maximum concentration
in plasma were determined by inspection of the raw data.
In all instances, the graphs of log plasma concentration
versus time were reasonably linear from 8 to 48 h. The
terminal elimination rate constant (kIl) was calculated as
the slope of this line, using linear least-squares regression
with reciprocal weighting; coefficients of determination ex-
ceeded 0.98 in all but a few cases (which all exceeded 0.90).
Elimination half-life was calculated as 0.693/k,1. The area
under the plasma concentration-time curve from 0 h to
infinity (AUC_OO) was the sum of the AUC from 0 to 48 h
(AUCO 48) (determined by trapezoidal rule) and AUC4.
(determined as plasma concentration at 48 h/ke,). The appar-
ent oral clearance was obtained from the quotient oral
dose/AUC,,. The urinary recoveries of lomefloxacin and
lomefloxacin conjugates were expressed as percentages of
dose. Analysis of variance and Dunnett's test were used to
test statistical significance of differences in the various
parameters in relation to treatment.
The mean values for plasma lomefloxacin concentrations
following each treatment are shown in Fig. 1; a slight delay
in absorption of lomefloxacin after eating is apparent. All
calculations were performed using exact sampling times,
which often deviated slightly from the nominal sampling
times shown in the figure.
(The mean [± standard error] values for concentrations in
plasma [micrograms per milliliter] not shown in Fig. 1 were
as follows: fasting-24 h, 0.37 ± 0.04; 32 h, 0.21 ± 0.03; and
48 h, 0.06 ± 0.01; standard-24 h, 0.36 ± 0.04; 32 h, 0.20 +
0.02; and 48 h, 0.05 ± 0.01; and high fat-24 h, 0.37 ± 0.04;
32 h, 0.18 ± 0.02; and 48 h, 0.06 ± 0.01.)
The derived pharmacokinetic parameters are given in
Table 1, which shows that the delay in lomefloxacin absorp-
tion resulted in a statistically significant (P < 0.001) increase
in time to maximum concentration in plasma following both
types of meal. The effects of the two meals did not differ.
There were no statistically significant differences (P > 0.05)
in any of the other parameters tabulated. The extents of
recovery of lomefloxacin in urine were essentially the same
after each treatment. There was no adverse effect attribut-
able to the drug in any subject, and the only change in
biochemical, hematological, or urinary parameters was a
slight lowering in hematocrit and hemoglobin as a result of
blood sampling. There were no unidentifiable or drug-related
crystals in any urine samples following dosing with lome-
floxacin.
In summary, the time to peak plasma lomefloxacin con-
centration following a carbohydrate meal or a high-fat meal
was prolonged by a mean of approximately 1 h, compared to
that seen in the fasting condition. The extent of absorption
was not significantly reduced by either type of meal, and
other aspects of the disposition of the drug were not affected
by food. These results are generally similar to those obtained
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TABLE 1. Pharmacokinetic parameters for lomefloxacin administered without or with fooda
Treatment Cmax Tmax t4/2 AUCO_ CLORAL fuLF) fu(LFC)(p.g/ml) (h) (h) (,ug. h/mI) (ml/min) (% of dose) (% of dose)
Fasting 3.76 (0.91) 1.45 (0.65) 8.54 (1.44) 36.58 (8.37) 193.3 (54.6) 67.6 (6.4) 8.2 (3.2)
Carbohydrate 3.12 (0.69) 2.45 (0.77) 8.15 (1.13) 33.30 (7.75) 211.4 (54.3) 63.6 (7.0) 6.7 (3.0)
High fat 3.28 (0.94) 2.50 (0.88) 8.46 (1.24) 34.35 (5.39) 199.1 (35.1) 66.5 (5.2)b 6.8 (3.6)b
Statistical significance (P) >0.05 <0.001 >0.05 >0.05 >0.05 >0.05 >0.05
a Values are means for 12 subjects, with standard deviation in parentheses. C Maximum concentration in plasma; Tmax, time to Cmax; t112, elimination
half-life; AUCO,, area under the plasma concentration-time curve from 0 h to infinity; CLORAL, apparent oral clearance;fu(LF) and f(LFc), urinary recoveries
of lomefloxacin and lomefloxacin conjugates, respectively.
b Mean for 11 subjects (incomplete urine collection from 1 subject).
previously with enoxacin (5), ciprofloxacin (2), ofloxacin (1),
and pefloxacin (3), for all of which absorption was slightly
delayed by administration with at least some types of meals.
In conclusion, lomefloxacin may be taken with or without
food, and the slight absorption delay caused by food is
unlikely to have clinically significant consequences, since
the extent of absorption is not reduced.
This work was supported by G. D. Searle, Crows Nest, New
South Wales, Australia.
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